2 weeks After its entire board resigned overnight, 23andMe will cut over 200 employees and its cancer research in an urgent bid to nurse the company back to healthFortune
The DNA-testing firm said in a Tuesday SEC filing, “there is substantial doubt about the company’s ability to continue.”
X